Objectives: Medication adherence with urgency urinary incontinence (UUI) treatment is challenging and the best assessment methodology is uncertain. We sought to describe adherence with anticholinergic (AC) versus placebo (P) by comparing pill counts and MEMSCAP event data and to identify factors associated with adherence.
U rgency urinary incontinence (UUI) is defined as the "complaint of involuntary loss of urine associated with urgency." 1 Approximately 5% to 10% of women experience UUI at least monthly with a negative impact on quality of life. 2 A recent metaanalysis of more than 40 randomized controlled trials of anticholinergic (AC) medications, the most frequent therapy for overactive bladder (OAB) and UUI, found reductions ranging from 0.9 to 4.6 incontinence episodes per day. 2 Although ACs are modestly effective, there is still a gap between observed and potential levels of treatment efficacy. Patient adherence may contribute to this gap. 2 Between 20% and 30% of all medication prescriptions are never filled, this can be as high as 50% for chronic disease medications. 3, 4 For AC medications, 65% to 80% of respondents reported discontinuation during a 12-month period. 5 Reasons for discontinuance included lack of efficacy and unwanted adverse effects. Little information on oral medication adherence is available for women affected by UUI. Furthermore, the best method to assess adherence in research studies is uncertain.
The AC versus Botulinum Comparison (ABC) trial was a randomized trial of women with idiopathic UUI. 6 Participants received either oral AC medication plus placebo (P) bladder injection versus oral P plus onabotulinumtoxinA (Botox) injection. This planned secondary analysis sought to (1) describe adherence to oral AC or oral P comparing the following 2 adherence methods: pill counts and MEMSCAP; (2) identify factors associated with adherence; and (3) explore the relationship between adherence and study outcomes. An improved understanding of adherence may allow targeted education and realistic expectations of treatment efficacy and adverse effects. 7 
METHODS
The ABC trial was a randomized, double-blind, double-P-controlled trial designed to compare the effects of intradetrusor onabotulinumtoxinA injection versus oral AC therapy to treat women with moderate to severe idiopathic UUI performed at 10 sites of the National Institutes of Health-funded Pelvic Floor Disorders Network. The methods and primary outcome of the ABC trial have been reported previously. 6, 8 Briefly, women with 5 or more UUI episodes on a 3-day prospective bladder diary were randomized to receive either a 100-unit intradetrusor injection of onabotulinumtoxinA and 6 months of oral P or a P saline intradetrusor injection and 6 months of a standardized regimen of AC medication. Subjects in the saline/AC group were started on solifenacin 5 mg daily for the first 2 months. Solifenacin was increased to 10 mg daily at month 2 and subsequently switched to trospium XR 60 mg daily at month 4 if symptoms were not adequately controlled on the basis of a Patient Global Symptom Control score of 1 to 3. 6 Participants assigned to the Botox/P group were similarly offered dose escalation. All oral study medications were discontinued at 6 months.
Anticholinergic medication or P was dispensed in a Medication Event Monitoring Systems (MEMSCAP) 6 TrackCap system (AARDEX Group, Ltd., Sion, Switzerland) composed of a MEMSCAP cap with a unique serial number and a standard medication bottle labeled with the subject's ID, randomization number, and unique bottle ID. The MEMSCAP system is fitted with a special closure that records the time and date of each opening and closing of the bottle through integrated microcircuitry. At the 2-, 4-and 6-month study visits, MEMSCAP data from the previous 2-month period were uploaded and stored in an encrypted format on centralized, secured servers (medAmigo; AARDEX Group, Ltd.). In addition, remaining capsules in the bottles were counted and the medication and bottles were returned to the pharmacy at each study visit. Both active and P capsules were overencapsulated and seemed identical, allowing for masked pill counting. No feedback was provided to participants regarding adherence after pill counting was performed.
Adherence estimates were calculated on the basis of both pill counts and MEMSCAP data. Study period (0-2, 2-4, and 4-6 months) and overall adherence estimates were calculated as the percent of expected doses taken. Because study medications were prescribed as once-daily medications, the expected dose for each dosing period was defined as length of the dosing interval measured in days. The number of days in each dosing period was calculated by taking the difference between study visits that occurred at injection visit, 2, 4, and 6 months ± 2 weeks. For example, the expected dose for the 2-to 4-month period was the number of days between the 2-and 4-month visits. To account for the initial dispensation day, 1 day was added to the overall and 0-to 2-month expected dose. The number of doses taken based on pill count was calculated as the number of pills dispensed minus the number of pills returned at the following visit. If a bottle was not returned, pill count adherence for that study period and the overall pill count adherence were not calculated. The number of MEMSCAP doses was the number of events recorded during the specified study period. A MEMSCAP dose/event was defined as an opening followed by closure of the MEMSCAP with at least 3 seconds between opening and closing. Events reported before the initial dispense date or after final return of the MEMSCAP were excluded from adherence calculations. Multiple events on a single day were each counted independently for up to a maximum of 3 events. Additional events within the 24-hour period were excluded from the calculations. If a MEMSCAP was not dispensed, was identified as faulty, or was not returned, MEMSCAP adherence for that study period and the overall MEMSCAP adherence were not calculated.
A composite adherence was calculated using the following algorithm: (1) if both pill count and MEMSCAP adherence estimates were available for a study period, then the composite adherence estimate was the average of the 2 individual estimates; (2) if only 1 of the 2 individual adherence estimates was available for a study period, then the composite adherence estimate for that study period was set to the adherence estimate for the available measure; and (3) if none of the individual adherence estimates was available for a study period, a composite adherence was not calculated. The overall composite adherence estimate for each subject was calculated as the average adherence across all study periods weighted by the duration of each period. Adherence was capped at 100%.
Statistical analysis was performed using SAS software, Version 9.2 (SAS Institute, Cary, NC). To compare adherence measures, Spearman rank correlation coefficients between MEMSCAP versus pill count data were calculated for each study period. Continuous measures of adherence calculated once per subject were compared between treatment groups using analysis of covariance techniques adjusting for the randomization stratification variables (previous AC exposure or drug naivete, baseline UUI severity [5-8 vs ≥9 UUI episodes per 3 days] and clinical site). Binary variables were compared using Cochran Mantel-Haenszel tests that accounted for randomization strata. Measures calculated by study period and drug dose were compared using a linear mixed model with adherence measure as the outcome, with terms for treatment group, study period (or drug dose/level) and the interaction of treatment group with study period (or drug dose/level) and covariates for each randomization stratification variable. Study participant was treated as a random effect variable to account for the correlation in outcomes over time within a participant. The association between adherence and daily dosing pattern was explored by calculating the Spearman rank correlation coefficient between overall composite adherence and the interquartile range of dosing times.
To identify potential factors associated with adherence, mixed models were used. For each potential predictor of interest, 2 models were fit for each outcome measure including the fixed effect of treatment group and site. The first model included the covariate only to see whether it is predictive of outcome or a treatment confounder. The second model included the covariate, the treatment by covariate interaction, and the treatment by month by covariate interaction to evaluate whether the prediction differs by treatment arms. Any factors significant at the 0.1 level for either of these models were included in the initial multivariable models, with the final model determined by stepwise variable reduction using a P value of 0.1 to retain variables in the model. Baseline age, body mass index, smoking status, race, ethnicity, education, drug naive status, incontinence severity, Overactive Bladder Questionnaire Short Form 9,10 score, and medication burden were considered as potential factors associated with adherence. To assess the relationship between adherence and study outcomes, the primary study analyses were repeated for the subset of the study population considered treatment adherent and additional analyses were conducted on the subset treated with actual AC medication. A participant was considered treatment adherent if she was 80% or more adherent during each study period based on the composite adherence measure. Data were analyzed on the basis of actual treatment received as opposed to randomized treatment. Any outcome data reported after initiation of off-protocol UUI treatments were censored. For continuous endpoints assessed over time, linear mixed models with terms for treatment group, study visit, and the interaction of treatment group with study visit and covariates for each randomization stratification variable were used. For analyses of binary outcome measures assessed over time, similar models were constructed using a robust Poisson regression model assuming Poisson distribution and log link. Aggregate binary measures of efficacy and safety were evaluated using Mantel-Haenszel tests that accounted for randomization strata.
RESULTS
Nearly all (247) of the 249 women randomized to AC medication or Botox injection received the intervention (126 received AC pill with saline injection and 121 received P pills with Botox injection.) Most subjects (241) were available for primary outcome analysis, and there were no significant group differences between treated subjects in any baseline characteristic including age, number of incontinence episodes, or history of any AC medication (Table 1) . By the first postintervention study visit at 1 month, both groups demonstrated a significant decrease in daily incontinence episodes that continued through the 6-month study period. 8 
Overall Adherence
As determined by the composite measure of pill count and MEMSCAP data, both groups had similar overall adherence in taking study pills (AC, 83.3% [16.8] vs P, 84.8% [13.8] ; P = 0.45), without differences by drug/dosing regimen or study period ( Table 2 ). Treatment groups also had similar overall dosing duration (AC, 176.6 [30.5]days vs P, 175.8 [25.5] days; P = 0.76), also without significant differences by drug/dosing regimen or study interval. Although more than 60% of the subjects in both treatment arms were at least 70% adherent within each study period, only 53% of women met the predetermined dichotomous criterion for "treatment adherent" (ie, at least 80% adherent at all 3 study phases). Correlation between adherence measured by pill counts versus MEMSCAP decreased over the treatment period (r = 0.53, 0.50, and 0.36 for each 2-month interval) with adherence estimates obtained via pill counts tending to be higher than estimates obtained via MEMSCAP and with a slight waning in adherence (by all measures) for 6 months (Figs. 1, 2) . Subjects with more variability in their dosing schedule time tended to be less adherent (r = 0.47, P < 0.0001). Figures 3 and 4 are limited to participants receiving active therapy. Figure 3 shows the adherence across the various dosages and Figure 4 shows adherence based on whether the subject received dose escalation/drug change.
Factors Associated With Adherence
With the use of adherence as a continuous measure, factors significantly associated with lower adherence included higher (worse) incontinence severity at baseline (ie, more frequent episodes of UUI), higher (better) baseline OAB quality of life scores for the AC group, and current smoking status overall (Table 3) . Examination of the parameter estimates shows that for every additional urgency incontinence episodes per day, compliance decreases by 1.7%. Although these findings are statistically significant, they may not represent a significant enough change to be clinically relevant. Similarly, the statistical relationship observed between OAB Quality of Life scores and adherence was not clinically meaningful. When treatment adherent (defined by at least 80% adherence using the composite measure from pill counts and MEMSCAP data) is used as a dichotomous variable, age, race, and baseline incontinence severity were factors appearing significant (P < 0.1) in univariate modeling, only race remained significant in the final multivariable model. In this patient cohort, white race was 76.9% treatment adherent whereas black or other races were 53.9% and 51.6% treatment adherent, respectively.
Relationship Between Adherence and Study Outcomes
Similar to the findings of the primary intention to treat analyses, there was no significant difference between treatment groups in the reduction of the frequency of episodes of urgency incontinence or improvements in quality of life within the subgroup of treatment-adherent women. To explore whether strict treatment adherent was temporally associated with treatment effect, we performed a subanalysis restricted to the subgroup of women randomized to receive active AC medication. For this analysis, we compared participants who were adherent (ie, those taking pills 5 or more days of 7 as assessed solely by MEMSCAP in the week before scheduled outcome assessment) versus those who were not.
The observed trend overall showed slightly more improvement for most of the outcomes measured, including more than 75% reduction from baseline in mean UUI episodes per day by diary, no UUI, and total scores from the Pelvic Floor Distress Inventory and Pelvic Floor Impact Questionnaire. However, none were statistically or clinically significant. At particular time points (4 and 6 months for reduction from baseline mean UUI episodes and 4 months for no UUI), these trends were not observed. A sensitivity analysis showed similar improvements in most, but not all, outcome measures when we excluded subjects with large discrepancies in adherence between pills counts and MEMSCAP (ie, >30% discrepancy). Overall, adherence based on MEMSCAP data was not associated with improved continence.
DISCUSSION
Medication adherence is considered important, especially for chronic conditions, but is poorly understood. In clinical care, prescribers hope for 100% adherence with oral medication, yet they are well aware of the reality of suboptimal adherence. Increased health care costs, health care use, and susceptibility to adverse drug reactions result from suboptimal treatment. 11 In OAB patients, Balkrishnan et al 12 found that every 10% increase in medication possession ratios resulted in a 5.6% reduction in annual health care costs. Effective interventions require attention to the multiple conditions and behaviors that influence decisions regarding adherence. 13 We did not find a statistically significant relationship between adherence and the study outcomes. Because this was a secondary analysis, it is possible that we were underpowered for this comparison. However, the differences observed were not clinically relevant. In this study, we confirmed that strict adherence with oral medications for urinary incontinence is low; only 53% of our subjects consistently maintained at least 80% adherence during each phase during the initial 6 months. Yeaw et al 11 found that 12-month adherence rates were lowest in patients on overactive bladder medications compared with other chronic therapies such as statins, oral antidiabetics, and angiotensin II receptor blockers (35% vs 61%, 72%, and 66%, respectively). Adherence in this study is likely higher than that of routine clinical care, given the highly structured environment of a randomized trial and careful 15 found adherence rates (measured by the percentage of patients with medication possession ratios of more than 80% for 1 year) of only 30% in a retrospective cohort study of OAB pharmacy claims data. Using data from a national prescription database, Norwegian investigators have also documented high discontinuation rates for OAB medications and a low proportion (60%) of adherence during treatment. 16 This study documents the importance of measuring medication adherence when measuring treatment efficacy because one should not assume that all prescribed medications are taken as directed. Similar to Liu et al, 17 we found that adherence may be underestimated using MEMSCAP and overestimated by using pill counts alone. We combined both measures of adherence in an attempt to provide a more accurate composite measurement of adherence. The correlation of adherence calculations using pill counts and MEMSCAP should inform future trial design and help advance our understanding of research methods for measurement of adherence. Our findings that adherence declines over time and subjects who were less consistent in their daily dosing schedule were less adherent overall are consistent with clinical experience.
It is likely that the relationship between smoking and decreased adherence is secondary to a general pattern of poor health behaviors. Others have found that higher levels of general health are associated with better adherence in multivariable analyses of medical claims studies. 15, 18 However, we found it somewhat paradoxical that women with worse incontinence were less adherent, yet women with better quality of life scores were also suboptimally adherent. This intriguing finding deserves further study and may be explained by differences in treatment expectations.
This study provides robust adherence information for oral UUI medication outside an industry-sponsored setting. Research strengths include multiple clinical sites, diversity of participants, and 2 methods of adherence assessment. Nonetheless, we noted multiple challenges in our attempts to measure adherence, including pill count patterns that may indicate that subjects did not follow study protocols. It is not uncommon for clinical patients to remove medication from a prescription bottle to fill a secondary "day-by-day" dispenser. Although we cannot confirm this behavior, this occurrence would have potentially decreased the accuracy of the MEMSCAP recordings. Finally, we cannot comment on adherence beyond the duration of our adherence follow-up measures at 6 months.
In conclusion, we believe that our findings show that adherence based on pill counts and MEMSCAP were reasonably correlated and similar in both the active and P groups for participants receiving oral UUI medication. Future studies are encouraged to further refine research measures of medication adherence as well as clinically useful methods to optimize adherence during standard clinical care.
